Difference between revisions of "Diagnostic size cutoffs"
Jump to navigation
Jump to search
(tweak name) |
m (tweak) |
||
| Line 12: | Line 12: | ||
|[[Papillary_renal_cell_carcinoma]] | |[[Papillary_renal_cell_carcinoma]] | ||
|- | |- | ||
|[[Atypical | |[[Atypical alveolar hyperplasia]] | ||
|<5 mm<ref name=Ref_WMSP114>{{Ref WMSP|114}}</ref> | |<5 mm<ref name=Ref_WMSP114>{{Ref WMSP|114}}</ref> | ||
|Adenocarcinoma in situ of the lung | |Adenocarcinoma in situ of the lung | ||
Revision as of 09:14, 25 February 2012
Diagnostic size cutoffs are cutoffs which (in part) define a diagnosis and are seen in a number of places in pathology. They are usually somewhat arbitrary by their nature; however, they often make sense from a biologic big picture/management perspective. It doesn't make sense to treat ADH and low-grade DCIS the same, as their behaviour is different.
In pathology, size matters. With other things equal, in the context of how tumours are currently evaluated, big tumours do worse than small tumours.
| Precursor | Cutoff for precursor | Cancer |
| Papillary adenoma of the kidney | <=0.5 cm | Papillary_renal_cell_carcinoma |
| Atypical alveolar hyperplasia | <5 mm[1] | Adenocarcinoma in situ of the lung |
See also
References
- ↑ Humphrey, Peter A; Dehner, Louis P; Pfeifer, John D (2008). The Washington Manual of Surgical Pathology (1st ed.). Lippincott Williams & Wilkins. pp. 114. ISBN 978-0781765275.